J George Quintana, MD
Neurology · Albuquerque, NMNPI 1831291590
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 44 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 15 manufacturers reported payments, led by AbbVie at 37.5% of the total. Reporting peaked in 2024 at $651 and has fallen 58.4% since, to $271 in 2025.
Across 44 payments — averaging $22.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$369
- Boston Scientific$152
- Novartis$118
- AstraZeneca$60
- Grifols USA, LLC$54
- SK Life Science, Inc.$40
- plus $191 from 9 others
What the payments were for
- Food & beverage$984100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 22 | $369 |
| Boston Scientific | 1 | $152 |
| Novartis | 5 | $118 |
| AstraZeneca | 2 | $60 |
| Grifols USA, LLC | 2 | $54 |
| SK Life Science, Inc. | 2 | $40 |
| Neurelis, Inc. | 2 | $40 |
| Johnson & Johnson | 1 | $23 |
| Lilly USA, LLC | 1 | $23 |
| C2n Diagnostics, LLC | 1 | $23 |
| Lundbeck LLC | 1 | $19 |
| Argenx US, Inc. | 1 | $19 |
| Eisai Inc. | 1 | $17 |
| Merz Pharmaceuticals, LLC | 1 | $14 |
| CSL Behring | 1 | $13 |
How this compares
$984 in reported general payments places this provider in the 55th percentile of 91 neurology providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Entacapone | 13 | $2,088 |
| Levetiracetam | 41 | $1,385 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 44 | $1,224 |
| Oxcarbazepine | 17 | $978 |
| Memantine Hcl | 46 | $847 |
| Primidone | 14 | $846 |
| Propranolol Hcl ErPropranolol Hcl | 24 | $838 |
| Teriflunomide | 20 | $742 |
| Carbamazepine | 13 | $671 |
| AmantadineAmantadine Hcl | 16 | $669 |
| Topiramate | 23 | $515 |
| Donepezil Hcl | 32 | $427 |
| Lamotrigine | 24 | $265 |
| Gabapentin | 23 | $251 |
| Baclofen | 11 | $205 |
Paid to pharmacies, not to this prescriber.
Other neurology in Albuquerque
- Elaine EdmondsAlbuquerque$610K
- Kader AbdelerahmanAlbuquerque$607K
- Timothy OwnbeyAlbuquerque$90K
- Gerson Suarez CedenoAlbuquerque$44K
- Corey FordAlbuquerque$27K
- Diksha MohantyAlbuquerque$20K
- Douglas BarrettAlbuquerque$19K
- Vanessa Licona SanjuanAlbuquerque$16K
- Daniel ShibuyaAlbuquerque$13K
- Alfred van BaakAlbuquerque$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.